Compare MPLX LP (MPLX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Tango Therapeutics Inc. — how do they compare? MPLX LP trades at $57.5 (market cap $57.70B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: MPLX LP is far larger — about 15.4× Tango Therapeutics Inc.'s market cap, and MPLX LP pays a 7.57% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals.
| MPLX | TNGX | |
|---|---|---|
Market Cap | $57.70B | $3.75B |
Volume | 561,167 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $60.51 | $32.90 |
52-Week Low | $48.53 | $7.50 |
Enterprise Value | $82.80B | $2.77B |
Dividend Yield | 7.57% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.91, up 0.14% with a bearish technical signal despite strong fundamentals. The company reported $11.47B revenue and $4.91B net income for 2025, with robust profitability margins (40.45% net margin, 33.95% ROE). Recent earnings show mixed results with Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 12% upside potential.
The investment case balances strong cash flow generation and dividend yield against energy market volatility risks. MPLX's fee-based midstream model provides revenue stability, but recent technical weakness and earnings misses warrant caution. The stock offers value with a 12.24 P/E ratio and dividend income potential, though investors should monitor Q3 2026 earnings due November 3rd for confirmation of business momentum.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
